Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 6, 1999, Pages 472-475

  El Zayadi, A ^a   Selim, O ^a   Haddad, S ^a   Simmonds, P ^a   Hamdy, H ^a   Shawky, S ^a  

^a Cairo Liver Center   (Egypt)

Author keywords

Chronic hepatitis C; Combination therapy; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; FOLLOW UP; GENOTYPE; HEMOLYSIS; HEPATITIS C; HISTOLOGY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; VIREMIA;

EID: 0032879845     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bassily S, Hyams KC, Fouad RA, Samaan M, Hibbs RG. A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. Am J Trop Med Hyg 1995;52:503-5.
2. Arthur RR, Hassan NF, Abdallah MY, El-Sharkawy MS, Saad MD, Hackbart BG, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg 1997;91:271-4.
3. Arthur RR. Epidemiology of HCV infection in Egypt. Med Comm 1996;67:4-7.
4. Lindsay KL. Therapy of hepatitis C. Overview Hepatology 1997;26(Suppl. 1):S71-7.
5. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. and the multicenter study group. A comparison of three interferon alpha 2b regimens for the long term of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
6. Davis GL, Lai JYN. Factors predictor of beneficial response to therapy of hepatitis C. Hepatology 1997;26 (Suppl. 1):S122-7.
7. El-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to α-interferon of Egyptian patients infected with hepatitis C virus genotype 4. Viral Hepatitis, 1996;3:261-4.
8. Garson JA, Brillanti S, Whithy K, Foli M, Deaville R, Masci C, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol 1995;45:348-53.
9. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo controlled study. J. Hepatol. 1996;25:591-8.
10. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin, Hepatology 1997;26(Suppl. 1):S 108-11.
11. Schalm SW, Hansen BE, Chemello L, Bellobnono A, Browner JL, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. A meta-analysis of individual patients' data from European centers. J Hepatol 1997;26:964-6.
12. Davidson F, Simmonds P, Ferguson C, Jarvis LM, Dow BC, Follett EAC, et al. Survey of major genotypes and subtypes of hepatitis C virus using R.F. L.P. of sequences amplified from the major 5″ non-coding region. J Gen Virol 1995;76:1197-204.
13. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(Suppl. 1):S112-21.
14. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alpha and ribavirin combination therapy in naïve patients with chronic hepatitis C. Scand J Infect Dis 1995;27:325-9.
15. Lai MY, Kao JH, Yang PM, Wang JI, Chen PJ, Chan KW, et al. Long term efficacy of ribavirin and interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
16. McHutchinson JG, Gordon SG, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med 1998;339:1485-92.
17. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon-α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
18. Reichard O, Norkrans G, Fyden A, Braconier JH, Sonnenborg A, Weiland O. Randomized double-blind placebo controlled trial of interferon 2b with and without ribavirin for chronic hepatitis C. The Swedish study group. Lancet 1998;351:83-7.
19. Mohamed MK, Rakha M, Soheir S, Saber M. Viral hepatitis C infection among Egyptians; the magnitude of the problem: Epidemiology and Laboratory approach of Egypt. Public Health 1996;2:78-111.